- Original article
- Open Access
Characterization of GH2 and GH42 β-galactosidases derived from bifidobacterial infant isolates
AMB Express volume 9, Article number: 9 (2019)
Bifidobacteria are among the first and most abundant bacterial colonizers of the gastrointestinal tract of (breast-fed) healthy infants. Their success of colonising the infant gut is believed to be, at least partly, due to their ability to metabolize available carbon sources by means of secreted or intracellular glycosyl hydrolases (GHs). Among these, β-galactosidases are particularly relevant as they allow bifidobacteria to grow on β-galactosyl-linked saccharidic substrates, which are present in copious amounts in the milk-based diet of their infant host (e.g. lactose and human milk oligosaccharides). In the present study we employed an in silico analysis to identify GH family 2 and 42 β-galactosidases encoded by typical infant-associated bifidobacteria. Comparative genome analysis followed by characterisation of selected β-galactosidases revealed how these GH2 and GH42 members are distributed among these infant-associated bifidobacteria, while their hydrolytic activity towards growth substrates commonly available in the infant gut were also assessed.
Bifidobacteria are common members of the human gut microbiota, and are especially abundant in the gastrointestinal tract (GIT) of healthy, breast-fed infants (Milani et al. 2017). The presence of bifidobacteria in the gut is believed to provide a number of health benefits for the human host, although the mechanisms by which such benefits are delivered are currently not fully understood (Arboleya et al. 2016; Milani et al. 2017). Bifidobacteria are saccharolytic microorganisms and their ability to utilize complex dietary glycans or host-derived mucins is an important property to assist in their establishment and persistence into the GIT (Koropatkin et al. 2012; Milani et al. 2015; Riviere et al. 2016). The saccharolytic metabolism of bifidobacteria is facilitated by a large array of carbohydrate degrading enzymes, in particular glycosyl hydrolases (GHs), which provide the capacity to directly or indirectly (through syntropy) utilize a range of glycan substrates available in the gut (Milani et al. 2015; Turroni et al. 2018a). Bifidobacteria commonly represent the dominant component of the gut microbiota of healthy, breast-fed infants (Roger et al. 2010), a phenomenon that is believed to be due in part by their ability to metabolize human milk oligosaccharides (HMOs), which contain one or more β-linked galactose moieties (Fuhrer et al. 2010). Among the glycosyl hydrolases encoded by bifidobacteria (Milani et al. 2015) β-galactosidases (which are members of GH families 2 and 42) (van den Broek et al. 2008) have been described to participate to the utilization of (human) milk and milk-based substrates (i.e. lactose, HMOs as well as GOS) in Bifidobacterium bifidum, Bifidobacterium longum subsp. infantis and Bifidobacterium breve (Garrido et al. 2013; Goulas et al. 2007; James et al. 2016; Miwa et al. 2010; Moller et al. 2001; O’Connell Motherway et al. 2013; Yoshida et al. 2012). In addition, β-galactosidases in B. bifidum can also participate to the degradation of mucin (Turroni et al. 2010), while in B. breve such enzymes are involved in the degradation of the plant polymer galactan (O’Connell Motherway et al. 2011).
Human milk glycans can be quite diverse and they are composed of 13 core structures generated through the elongation of lactose at the reducing end with one or more β1,3-linked lacto-N-biose (type-I chain) and/or β1,3/6-linked N-acetyllactosamine units (type-II chain) (Urashima et al. 2012). These core structures (including lactose itself) can in turn be substituted at terminal positions by fucose connected via α1,2/3/4 links, and/or sialic acid residues attached by α2,3/6 links (Smilowitz et al. 2014). Notably, HMOs are especially rich in type-I chains and constitute a characteristic feature of human milk (Urashima et al. 2012).
Some of the glycosidic linkages and monosaccharides found in HMOs are also present in mucins found in the intestine, for example the presence of β-linked galactose and N-acetyl-glucosamine, as well as fucose and sialic acid residues which are substituted to mucin via α1,2/3/4 and α2,3/6 linkages (Tailford et al. 2015).
Recent genome analyses have highlighted metabolic pathways responsible for the degradation of HMOs and mucin-type O-glycans in certain infant-derived bifidobacteria. With regards to HMO utilization it has been shown that B. bifidum and B. longum subsp. infantis can utilize many different HMOs directly (Asakuma et al. 2011; Garrido et al. 2016; Sela 2011; Ward et al. 2007). In contrast, B. breve and B. longum subsp. longum can only metabolize a small number of these directly, thus relying on cross-feeding strategies (Asakuma et al. 2011; Egan et al. 2014; LoCascio et al. 2007; Ward et al. 2007). B. bifidum is the only bifidobacterial species described so far to be able to utilize mucin-type O-glycans (Turroni et al. 2010), and the products of (extracellular) mucin degradation constitute growth substrates for other (bifido)bacterial species, revealing that bifidobacteria can adopt a syntrophic strategy to access different substrates available in the gut (Egan et al. 2014; Turroni et al. 2018b).
The complex structural and functional heterogeneity of HMOs in mother’s milk is presumed to be essential in conferring the bifidogenic activity and associated health benefits to the host, yet it also represents the main limitation for the deliberate incorporation of HMOs in infant formulations (Akkerman et al. 2018). For this reason alternative ways of recreating the beneficial effects of human milk have focused on the enzymatic production of other non-digestible, lactose-derived prebiotics, such as GOS produced by β-galactosidases that have transgalactosylation activities (Macfarlane et al. 2008).
Based on the above, the relevance of diet-based, lactose-derived oligosaccharides (e.g. HMOs and GOS) in supporting bifidobacterial establishment and persistence in the gut is obvious, especially during early life when bifidobacteria are particularly abundant (Milani et al. 2017). The current study focused on a survey and subsequent hydrolytic characterization of (selected) β-galactosidases identified from sequenced strains of bifidobacterial species which have been previously shown to be members of the infant gut microbiota (i.e. B. breve, B. bifidum, B. longum subsp. longum and B. longum subsp. infantis) (Lewis and Mills 2017; Milani et al. 2017; Turroni et al. 2012). Following comparative genome analysis, our analysis focused on a number of selected β-galactosidases of which hydrolytic capabilities were assessed for various β-galactoside-containing substrates.
Materials and methods
In silico genome analysis to identify putative β-galactosidase-encoding genes
For comparative purposes, genomic datasets, consisting of 34 genome sequences (Table 1) from four representative infant-derived bifidobacterial (sub)species (i.e. B. breve, B. bifidum, B. longum subsp. longum and B. longum subsp. infantis) were retrieved from GenBank (https://www.ncbi.nlm.nih.gov/genbank). Of the corresponding 34 bifidobacterial strains, we selected six strains as representative reference strains for our analysis as their genome had been sequenced to completion and because these strains are available within our culture collection [i.e. B. breve UCC2003 (GenBank: CP000303), B. breve JCM 7017 (GenBank: CP006712), B. breve JCM 7019 (GenBank: CP006713), B. bifidum LMG 13195 (WGS: AMPL01000000), B. longum subsp. longum NCIMB 8809 (GenBank: CP011964) and B. longum subsp. infantis ATCC 15697 (GenBank: CP001095)]. The selected genomes were searched for predicted β-galactosidase-encoding genes on the basis of a functional annotation supported by PFAM analysis (http://pfam.xfam.org/), combined with information retrieved from the Cazy database (http://www.cazy.org). Predictions were refined using comparative genome analysis with detection of orthologous β-galactosidase-encoding genes across genomes using BLASTP searches (Altschul et al. 1990). BLASTP alignments were performed using a stringency of 50% of identity across 50% of the length of the examined proteins, with a cut-off E-value of < 0.0001. Predicted β-galactosidase-encoding genes were then grouped in clusters of orthologs using the cd-hit pipeline (http://weizhongli-lab.org/cd-hit/) with a clustering threshold of 70% identity across 90% of the corresponding protein length (Bottacini et al. 2014).
Phylogenetic inference was conducted using the MEGA7 suite (http://www.megasoftware.net/). Protein sequence alignments were performed using the Muscle module available within MEGA7 and the resulting phylogenetic tree was built using the neighbour joining approach with statistical assessment based on 1000 bootstrap replicates.
Growth conditions and strain manipulation
Bifidobacterial strains were cultured in de Man Rogosa and Sharpe (MRS) medium supplemented with cysteine-HCl (0.05% w/v) and incubated at 37 °C degrees under anaerobic conditions using an anaerobic chamber (Davidson and Hardy, Belfast, Ireland). L. lactis strain NZ9000 (University of Groningen, The Netherlands) was selected for cloning (de Ruyter et al. 1996), overproduction and purification purposes as several bifidobacterial GH-encoding genes had previously been successfully cloned and expressed in this host (James et al. 2016; O’Connell et al. 2013; O’Connell Motherway et al. 2013). L. lactis NZ9000 was grown in M17 broth (Oxoid, UK) supplemented with 0.5% glucose (GM17) at 30 °C degrees (Terzaghi and Sandine 1975). L. lactis NZ9000 cells carrying (suspected) recombinant plasmids were selected on GM17 agar containing chloramphenicol (Cm 5 µg ml−1), and supplemented with X-gal (5-bromo-4-chloro-3-indolyl-ß-d-galactopyranoside) (40 µg ml−1) to visually identify recombinant clones expressing β-galactosidase activity.
Chromosomal DNA was isolated from B. breve UCC2003, B. bifidum LMG 13195, B. longum subsp. longum NCIMB 8809 and B. longum subsp. infantis ATCC 15697 as previously described (O’Riordan and Fitzgerald 1998). Plasmid extraction from L. lactis was achieved using the Roche High Pure Plasmid Isolation Kit (Roche Diagnostics GmbH, Mannheim, Germany). For L. lactis an initial lysis step was included where cells are incubated in lysis buffer containing 30 mg ml−1 of lysozyme for 30 min at 37 °C. Oligonucleotide PCR primers used in the study were synthesized by Eurofins (Ebersberg, Germany; Table 2). Standard PCRs were performed using Thermo Scientific Extensor Hi-Fidelity PCR Master mix (Thermo Scientific), while high fidelity PCR was achieved using Q5 High-Fidelity DNA Polymerase (New England BioLabs, New Brunswick). PCR fragments were purified with Roche High Pure PCR Product Purification Kit (Roche Diagnostics GmbH). Plasmid pNZ8150 was used as cloning and nisin-inducible expression vector. DNA fragments encompassing predicted β-galactosidase-encoding genes and the pNZ8150 vector were restricted with specific restriction enzymes (Table 2) according to the supplier’s instructions (Roche Diagnostics, East Sussex, United Kingdom). Ligation was achieved with T4 DNA ligase according to the manufacturer’s instructions (Promega, Wisconsin, USA, worldwide.promega.com). Electroporation of (ligated) plasmid DNA into L. lactis was performed as described previously (Wells et al. 1993).
Protein overproduction and purification
For bifidobacterial protein overproduction 0.4 ml of M17 broth supplemented with 0.5% glucose was inoculated with a 2% inoculum of L. lactis strain harbouring the pNZ8150 cloning vector containing a (predicted) β-galactosidase-encoding gene, and cultivated at 30 °C until the culture reached an Optical Density (OD600 nm) of 0.5. At this point targeted protein expression was induced by the addition of filter sterilised cell free supernatant of a nisin-producing strain L. lactis NZ9700 (0.2% v/v) (de Ruyter et al. 1996) and incubation was continued at 30 °C for 90 min. Cells were harvested by centrifugation (5000 rpm for 10 min), the obtained pellet was recovered in lysis buffer (50 mM sodium phosphate buffer, pH 8; 300 mM NaCl; 10 mM Imidazole) and cells were disrupted by bead beating (1 min, three times). Cell debris was removed by centrifugation (15,000 rpm for 20 min at 4 °C) and the resulting supernatant, representing the crude cell extract, was used for (His-tagged) protein purification using a nickel-nitrilotriacetic acid column (Qiagen GmbH) according to the manufacturer’s instructions (QIAexpressionist, June 2003). Elution fractions were analysed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), as described previously (Laemmli 1970), on a 12.5% polyacrylamide (PAA) gel. After electrophoresis, PAA gels were fixed and stained with Coomassie brilliant blue to identify fractions containing the purified protein. For molecular weight estimation of (purified) proteins the Prestained Protein Marker, Broad Range (7–175 kDa) was used (New England BioLabs, Hertfordshire, United Kingdom).
Beta-galactosidase assay: crude cell extract
Colorimetric and spectrophotometric assay was performed to evaluate the hydrolytic activity of predicted β-galactosidases towards the artificial substrate O-nitrophenyl β-d-galactopyranose (ONPG assay). This assay was performed at 30 °C according to a previously published protocol (Miller, Cold Spring Harbor, 1972). Following the development of a yellow color the reaction was terminated by the addition of 250 µl 1 M sodium carbonate. This was followed by measurement of absorbance at a wave length of 420 nm. Calculation of β-galactosidase activity was performed according to the following formula: β-gal unit = 1000*OD420 nm/Time*V*OD600 nm, with incubation time of 5 min (or longer if required) and volume of resuspended pellet (V) of 0.05 ml.
Hydrolysis assay and product analysis
Hydrolysis assays of β-galactosidase activity were performed on the following commercially available substrates: lactose, lactulose, two different galactotrioses (Galβ1-4Galβ1-4Gal and Galα1-3Galβ1-4Gal), two different galactobioses (Galβ1-6Gal and Galβ1-4Gal), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 2′-fucosyllactose (2′-FL) and 3-fucosyllactose (3-FL). The hydrolysis assays were performed using the following conditions: 250 µl enzyme solution was incubated with 0.1 mg ml−1 of a particular carbohydrate in MOPS [3-(N-morpholino) propanesulfonic acid] buffer pH 6.5 in a total volume of 1 ml at 37 °C. Aliquots of 250 μl were collected after 1, 3 and 24 h from the start of the reaction and following collection samples were immediately heated at 80 °C for 5 min in order to terminate the reaction, after which they stored at − 20 °C until analysis by high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD) employing a CarboPac PA1 (Thermo Scientific) analytical-anion exchange column (dimensions, 250 mm by 4 mm) with a CarboPac PA1 (Thermo Scientific) guard column (dimensions, 50 mm by 4 mm) and a detector (ED40) in the pulsed amperometric detection PAD mode (Dionex, Thermo Scientific). Elution was performed at a constant flow rate of 1.0 ml min−1 at 30 °C using the following eluents for the analysis: (A) 200 mmol NaOH, (B) 100 mmol NaOH, 550 mmol sodium acetate (NaAC), and (C) Milli-Q water. The elution gradient is reported in Table 3. The obtained data sets were then analysed employing CHROMELEON software Ver.6.70 (Dionex, Thermo Scientific).
Comparative analysis of β-galactosidase-encoding genes
In order to identify putative β-galactosidase-encoding genes of infant-associated bifidobacterial strains, we initially selected the genomes of six strains to act as representatives for four bifidobacterial (sub) species (see “Materials and methods” section) that are typically prevalent and abundant in the (healthy) infant gut microbiota.
Putative β-galactosidase-encoding genes were identified on the genome sequence of each of these six reference strains (representing four species) based on manual searches and cross-validation of the obtained result with PFAM searches and Cazy database (see “Materials and methods”). The obtained list of predicted β-galactosidase-encoding genes was then used for further comparative analyses, aimed at identifying homologous genes across a more extensive set of 34 bifidobacterial genomes, belonging to the same (sub)species as the reference set (Table 1). Employing this comparative search approach we established that the total number of predicted GH2 and GH42 β-galactosidase-encoding genes encoded by (34 representatives of) these four bifidobacterial species is 137, of which 44, 45 and 48 were assigned to B. breve, B. bifidum and B. longum subsp. longum spp., respectively (Additional file 1: Table S1).
Comparative sequence analysis and phylogeny of predicted β-galactosidase genes
To establish if a putative β-galactosidase-encoding gene is represented by homologs across other strains or (sub)species, we organized the 137 identified β-galactosidases in 18 orthologous families (here referred as clusters based on a cut-off value of 70% of similarity over 90% of sequence length; see “Materials and methods”) (Additional file 1: Figure S1). This analysis revealed that members of each of the 18 orthologous clusters are variably distributed across a given species, where certain β-galactosidases seem to be more species-specific (e.g. Clusters 1–3 for B. bifidum, Clusters 4–6 for B. breve and Clusters 7–8 for B. longum subsp. longum), while others are present among all members of the four (sub)species (e.g. Cluster 15) (Fig. 1 and Additional file 1: Table S1).
As mentioned above comparative sequence analysis organized the 137 identified β-galactosidases into 18 clusters of orthology (Fig. 1). A subsequent analysis was carried out in order to establish the phylogenetic relationships between bifidobacterial β-galactosidases. This analysis resulted in the generation of a phylogenetic tree which subdivided these 137 genes into two distinct clades, corresponding to members that either belong to GH family 2 or GH family 42 (Fig. 2). Within these GH2 and GH42 clades, our analysis revealed that the β-galactosidase-encoding genes are further distributed across 14 distinct phylogenetic groups (or subclades defined by nodes of bootstrap value above 90%), where genes from strains belonging to the same species often cluster together (Fig. 2).
Cloning of bifidobacterial β-galactosidase-encoding genes
Based on the outcome of the phylogenetic analyses, a total of 20 most diverse β-galactosidases (present in the six representative genomes available within our culture collection, while also considering practical limitations of cloning this large number of genes) were selected as candidates for further experimental validation, which in most cases locate in separate branches of the phylogenetic tree (Fig. 3a). This selection therefore captures much of the observed diversity among the identified (putative) β-galactosidases (Fig. 3). Notably, of these 20 selected β-galactosidases, four (corresponding to locus tags B216_08266, Bbr_0529, B8809_0415 and Blon_2016) are orthologous genes within Cluster 15, of which members are present across all four infant-derived bifidobacterial (sub)species, while the remaining 16 selected genes are present only within certain (sub)species (Fig. 3b).
In order to investigate if the 20 putative β-galactosidase-encoding genes as selected above do in fact encode this enzymatic activity, cloning and (over)expression of each of these bifidobacterial genes in Lactococcus lactis was performed. The 20 β-galactosidase-encoding genes were therefore amplified by PCR using primer pairs, one of which included a six His-tag-encoding sequence (to aid in subsequent purification), and cloned into a nisin-inducible expression vector in L. lactis (see “Materials and methods”). Two out of the 20 predicted β-galactosidase-encoding genes (corresponding to locus tags B216_06500, B216_09411) appeared to be unclonable in L. lactis (as based on multiple failed attempts). One explanation could be the plasmid instability due to the (size of the) inserted gene, or toxicity of their products in the cloning host. In one case (i.e. Blon_2123 from B. longum subsp. infantis ATCC 15697), we found that the cloned gene contained a stop codon located 100 bp downstream of the start of the gene, thus making this a pseudogene. It is worth mentioning that BLAST analysis of this particular sequence against the deposited genome sequence of B. longum subsp. infantis ATCC 15697 showed that the publicly available sequence does not contain a stop codon at this point, suggesting that this mutation may be unique to our stock of B. longum ATCC 15697 (NB. the chromosomal sequence of this stock was verified by sequence analysis of a PCR product that encompassed the relevant section of Blon_2123). The obtained L. lactis transformants (or at least a proportion of the colonies corresponding to a given transformation) from the remaining 17 cloning efforts were in 14 cases shown to form easily identifiable blue colonies on plates including the chromogenic substrate X-gal (yet in the absence of the inducer nisin) (Table 4). This result clearly indicates that the majority of the cloned genes indeed encodes a β-galactosidases active on this artificial substrate. In three cases (i.e. corresponding to the cloning of genes with locus tags Bbr_0285, Bbr_0310 and B7017_2031) transformants only formed white colonies (though they contained the expected recombinant plasmid as verified by sequencing), suggesting that either the encoded product does not encode a β-galactosidase capable of cleaving X-Gal, or that the cloned gene was not (highly) expressed or its product not properly folded (Table 4). The plasmid content of a selection of positively identified clones for each cloning was sent for sequencing to validate sequence integrity of the cloned gene. In summary, of the total of 20 selected (putative) β-galactosidase-encoding genes, 17 were successfully cloned (as an intact gene), of which 14 turned out to encode β-galactosidase activity as based on the applied X-gal plate assay.
β-galactosidase assays: crude cell extract
In order to determine if the products of the 17 cloned genes were active on substrates other than or in addition to X-gal, β-galactosidase assays were conducted using crude cell extracts obtained from individual, nisin-induced cultures of L. lactis in which a predicted β-galactosidase-encoding gene had been cloned (Additional file 1: Figure S2). Out of the 17 different crude cell extracts tested, nine were shown to exhibit high activity against the artificial substrate ONPG (between 5000 and 14,000 Miller units) (Fig. 4). In addition, five crude cell-free extracts were demonstrated to display a relative low level of enzymatic activity (between 400 and 2000 Miller units) to cleave this ONPG substrate, while the remaining three crude cell-free extracts (corresponding to the expressed proteins specified by Bbr_0285, Bbr_0310 and Bbr_1689/1690) failed to show hydrolytic activity against this substrate (baseline set at 400 Miller units) (Fig. 4). It is worth mentioning that Bbr_0285 and Bbr_0310 also did not form blue colonies on plates, thus providing further confirmation of their presumed inactivity as β-galactosidases (at least on the substrates tested, though lack of activity may also be due to lack of expression or protein misfolding).
Protein overproduction, purification and hydrolysis assay
All cloned (putative) β-galactosidase-encoding genes were then utilized for protein overproduction and subsequent His6-tagged protein purification using the L. lactis nisin-inducible protein production system (see “Materials and methods”). In order to verify the success of these steps, individually expressed and purified proteins were visualised by SDS-PAGE analysis followed by staining with Coomassie Brilliant Blue (Additional file 1: Figure S2). In order to assess substrate specificity of each of the 17 cloned (predicted) bifidobacterial β-galactosidases, qualitative hydrolysis assays by HPAEC-PAD analysis were performed using a number of (β-)galactosidic linkage-containing carbohydrates. The (putative) β-galactosidases were first tested for hydrolytic activity towards lactose, lactulose and β-d-galactotriose (Galβ1-4Galβ1-4Gal) (Table 4). The obtained results demonstrate that the purified proteins exhibited varying ability to cleave these different sugars. In the reaction with lactose the best activity (i.e. complete or partial hydrolysis of the substrate observed within the first hour of reaction) was exhibited by the proteins corresponding to Bbr_0010, Bbr_0529 and Bbr_1552 (all from B. breve), B216_08266 (from B. bifidum), B8809_0415, B8809_0611 and B8809_1361 (all from B. longum subsp. longum), and Blon_2016 (from B. longum subsp. infantis) (Table 4). When the reaction was performed with lactulose the most active proteins were those corresponding to locus tags Bbr_0529, Bbr_1552, B216_08266, B8809_0415, B8809_1361, Blon_2016 and Blon_2416 (Table 4). When the hydrolysis reaction was performed with the substrate β-d-galactotriose (Galβ1-4Galβ1-4Gal), the proteins corresponding to locus tags Bbr_0420, Bbr_0529, B216_08266, B216_08730, B8809_0321, B8809_0415, Blon_2016 and Blon_2416 were shown to hydrolyse the substrate within the first hour of the applied reaction conditions (Table 4). Following these three tests it was decided to eliminate the proteins corresponding to locus tags Bbr_0285, Bbr_0310, Bbr_1689/90, B216_8730, B216_09623 and B7017_2031 from further analyses because they were shown to be unable to hydrolyse any of the sugars tested. Notably, among these negatives are Bbr_0285 and Bbr_0310, which also did not show activity towards X-gal or ONPG substrates (Table 4; Fig. 4). In addition Bbr_1689/90, B216_09623 and B7017_2031 showed discordant activity towards hydrolytic activity towards X-gal, ONPG and lactose substrates. For this reason we decided to test their hydrolytic activity also on crude cell extract (which represents an unpurified enzyme; our purification method could have caused inactivation of the enzyme). Absence of protein expression was not considered to be the reason for the lack of activity of these enzymes because all these proteins were successfully overproduced and purified (Additional file 1: Figure S2). Based on the results of the hydrolysis assay on crude cell extracts, B216_09623 and B7017_2031 were shown to be capable of lactose hydrolysis, thus suggesting that the protein purification may have negatively affected their activity. Hydrolysis assays employing the remaining eleven β-galactosidases were then performed utilizing commercially available β-galactosyl-containing structures (including HMOs and GOS) as potential substrates. In the case of galactobiose (Galβ1-6Gal), clear hydrolysis activity was obtained when the reaction was performed with the proteins corresponding to locus tags Bbr_0529, Bbr_1552, B216_08266, B8809_0415 and Blon_2016. When the substrate galactotriose Galα1-3Galβ1-4Gal was used, no activity was detected within 24 h for any of the proteins tested, whereas four proteins (corresponding to Bbr_0420, Bbr_1552, B8809_0321, Blon_2416) were shown to be able to cleave galactobiose Galβ1-4Gal (Table 5). In order to further characterize the identified predicted β-galactosidases, their ability to hydrolyse the following carbohydrates, representing a selection of (β-linked galactose-containing) HMOs: lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 2′-fucosyllactose (2′-FL) and 3-fucosyllactose (3-FL) (Table 5). In the reaction with LNT the highest activity (positive within the first hour of reaction) was exhibited by the proteins corresponding to locus tags Bbr_0529 and Bbr_1552 (from B. breve), B216_08266 (from B. bifidum), B8809_0415, (from B. longum subsp. longum), and Blon_2016 (from B. longum subsp. infantis) (Table 5). When the reaction was performed with LNnT as a substrate, the most active proteins were those corresponding to locus tags Bbr_0010, Bbr_0529, Bbr_1552, B216_08266, B8809_0415, B8809_0611, B8809_1361 and Blon_2016 (Table 5). When the hydrolysis reaction was performed with the substrate 2′-FL, it was found that none of the proteins is active on this substrate (Table 5). The last sugar tested was 3-FL, and in this case the most active proteins were Bbr_0420, Bbr_0529, B216_08266, B8809_0321, B8809_0415, B8809_0611, B8809_1361 and Blon_2016 (Table 5).
In the current work we investigated β-galactosidase enzymes belonging to four bifidobacterial species B. breve, B. bifidum, B. longum subsp. longum and B. longum subsp. infantis, all of which are commonly found in healthy, breast-fed infants. Our analysis clearly shows that multiple distinct β-galactosidases are encoded by these infant-derived bifidobacterial species (Additional file 1: Table S1) with a partial overlap between their hydrolytic activities (Tables 4 and 5). Notably, for some of the identified β-galactosidases the involvement in utilization of galacto-oligosaccharides and/or host-derived glycans has previously been reported (Additional file 1: Table S1). Of note, some of the clusters from our comparative analysis appeared to be species specific, suggesting that certain β-galactosidase encoding genes are only found within certain species. For example the enzymes belonging to Clusters 1, 2, 3, 6 and 9 contain a wide range of B. bifidum β-galactosidases which represent homologs of BbgIII (NCIMB 41171), BbgI (NCIMB 41171), BbgIV (NCIMB 41171), BIF2 (DSM 2015) and BIF1 (DSM 20215), respectively. Notably, these enzymes have previously been reported to be capable of GOS synthesis (Additional file 1: Table S1) (Goulas et al. 2007; Miwa et al. 2010; Moller et al. 2001).
Our comparative analysis was used as a guide to select 20 candidates to be used for further assessment of β-galactosidase activity towards a number of substrates including a range of selected β-galactosyl-containing structures. Cloning efforts of the selected genes resulted in the successful overexpression and purification of 17 presumed β-galactosidases, of which hydrolytic activity was further assessed on a variety of substrates. The obtained findings revealed that the majority of the expressed enzymes indeed exhibit β-galactosidase activity. However, these β-galactosidases clearly differ from each other in their substrate specificity, since some of the enzymes are active on nearly all tested substrates, while others appear to be quite specific and merely hydrolyse one or two substrates.
Of note, the enzymes that are capable of hydrolysing the broadest range of selected substrates are members of Cluster 15 and are also widespread across the four (sub)species (i.e. Bbr_0529, B216_08266, B8809_0415 and Blon_2016), suggesting that these genes encode conserved β-galactosidase activities. Besides, enzymes of Cluster 15 appear to be homologous to the previously identified BbgII (from B. bifidum NCIMB 41171), which is capable of both GOS hydrolysis and synthesis (Goulas et al. 2007; Miwa et al. 2010; Moller et al. 2001) (Fig. 1). Notably, some of the β-galactosidases represented by this cluster have previously been shown to be involved in the utilization of either GOS and HMOs (Additional file 1: Table S1). In particular, it has been shown that Blon_2016 from B. longum subsp. infantis ATCC 15697 represents a β-galactosidase possessing hydrolytic activity towards LNT and LNnT, as well as GOS (Garrido et al. 2013), which is indeed confirmed by our observations (Tables 4 and 5).
Another member of Cluster 15 is the β-galactosidase encoded by Bbr_0529, which is required for the utilization of GOS and certain HMOs by B. breve UCC2003 (James et al. 2016; O’Connell Motherway et al. 2013), being consistent with our observed hydrolytic activities towards the majority of tested substrates including galactobiose, galactotriose, but also the central moieties of type I and type II HMOs (Tables 3, 4). As type I chains represent the most abundant HMO core structure in human milk (Urashima et al. 2012), the prevalence of Cluster 15 members across all four infant-derived bifidobacterial (sub)species (Fig. 3b) and observed ability to cleave LNT (but also LNnT) (Table 4) supports their relevance to bifidobacteria in obtaining access to substrates derived from a human milk-based diet.
Surprisingly, one of the β-galactosidases whose product was shown to be incapable of hydrolysing lactose or lactulose is Bbr_0420, which was instead shown to be active towards d-galactotriose Galβ1-4Galβ1-4Gal (Table 4). Previous studies established that Bbr_0420, a β-galactosidase which is upregulated when B. breve UCC2003 is grown on purified GOS (O’Connell Motherway et al. 2013), seems to be dedicated to the hydrolysis of d-galactotriose, which in turn is produced from the extracellular degradation of potato galactan in this strain (O’Connell Motherway et al. 2011). The transcription of this gene is, however, not induced when B. breve UCC2003 is grown on lactose and certain HMOs (e.g. LNT or LNnT) (James et al. 2016). Bbr_0420 from B. breve UCC2003 and its homologue B8809_0321 from B. longum subsp. longum NCIMB 8809 (both belonging to Cluster 13) were shown here to hydrolyse galactobiose (Galβ1-4Gal) and galactotriose (Galβ1-4Gal-β1-4Gal), but incapable of hydrolysing either LNT or LNnT. This suggests that they represent β-galactosidases with a narrow substrate specificity, which is directed towards β1,4 galactosidic links (Tables 4, 5). Interestingly, a recent study has associated a homolog corresponding to this β-galactosidase and located within the galactan cluster of B. longum AH1206 (BL1206_0411) with the persistence of this strain in the GIT tract (Maldonado-Gomez et al. 2016). This finding represents another indication of the role played by β-galactosidases and their dietary galactose-containing substrates in promoting bifidobacterial colonization.
Notably, purified Bbr_0010 from B. breve UCC2003 has previously been reported to hydrolyze lactose and LNnT (James et al. 2016), while Bbr_1552 represents a β-galactosidase with a broader substrate specificity, being involved in the hydrolysis of GOS, as well as lactose, LNT and LnNT in this strain (James et al. 2016; O’Connell Motherway et al. 2013), which is also consistent with our observations. Interestingly, a previous study employing a Tn5-based random mutagenesis system in B. breve UCC2003 identified Bbr_0010 as the main β-galactosidase responsible for lactose utilization in this strain (Ruiz et al. 2013). Based on our analysis this enzyme does indeed hydrolyse lactose (as well as LNnT) and the corresponding gene is conserved across B. breve (as Cluster 5 members).
Two interesting cases are constituted by B8809_0611 (Cluster 7) and B8809_1361 (Cluster 8) from B. longum subsp. longum NCIMB 8809 as these two β-galactosidases show similar hydrolytic profile and are particularly active towards LNnT (type II chain) despite being member of two different clusters (Tables 4 and 5). Cluster 7 member Blon_2334 from B. longum subsp. infantis ATCC 15697 has been described as a β-galactosidase responsible for degradation of lactose and type II HMOs, but not type I HMOs (Yoshida et al. 2012), being consistent with what we observed for B8809_0611. In contrast, B8809_1361, which shows a hydrolytic profile similar to Blon_2334 and B8809_0611, belongs to a different cluster (Cluster 8). Finally, B8809_1361 is only present in certain strains of B. longum subsp. longum, and perhaps constitutes an auxiliary β-galactosidase responsible for degradation of lactose and type II HMOs in this subspecies (Additional file 1: Table S1).
In conclusion, the information collected in this study highlights the importance of GHs in bifidobacterial saccharolytic metabolism, in particular β-galactosidases which are involved in the utilization of a range of substrates such as lactose, HMOs, and GOS, found as part of the milk-based infant diet. The qualitative assay presented in this study provides a clear insight on the diversity of β-galactosidases in terms of substrate specificity. In fact, some appear to be more specialized towards milk-based substrates, while others are specific for plant-derived substrates. Therefore, the findings presented here constitute a solid foundation for future studies on bifidobacterial β-galactosidases and further investigation on the role of milk-derived substrates in establishing bifidobacterial predominance in the infant GIT.
Akkerman R, Faas MM, de Vos P (2018) Non-digestible carbohydrates in infant formula as substitution for human milk oligosaccharide functions: effects on microbiota and gut maturation. Crit Rev Food Sci Nutr. https://doi.org/10.1080/10408398.2017.1414030
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215(3):403–410
Arboleya S, Watkins C, Stanton C, Ross RP (2016) Gut bifidobacteria populations in human health and aging. Front Microbiol 7:1204
Asakuma S, Hatakeyama E, Urashima T, Yoshida E, Katayama T, Yamamoto K, Kumagai H, Ashida H, Hirose J, Kitaoka M (2011) Physiology of consumption of human milk oligosaccharides by infant gut-associated bifidobacteria. J Biol Chem 286(40):34583–34592
Bottacini F, O’Connell Motherway M, Kuczynski J, O’Connell KJ, Serafini F, Duranti S, Milani C, Turroni F, Lugli GA, Zomer A, Zhurina D, Riedel C, Ventura M, van Sinderen D (2014) Comparative genomics of the Bifidobacterium breve taxon. BMC Genomics 15:170
de Ruyter PG, Kuipers OP, de Vos WM (1996) Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol 62(10):3662–3667
Egan M, Motherway MO, Kilcoyne M, Kane M, Joshi L, Ventura M, van Sinderen D (2014) Cross-feeding by Bifidobacterium breve UCC2003 during co-cultivation with Bifidobacterium bifidum PRL2010 in a mucin-based medium. BMC Microbiol 14:282
Fuhrer A, Sprenger N, Kurakevich E, Borsig L, Chassard C, Hennet T (2010) Milk sialyllactose influences colitis in mice through selective intestinal bacterial colonization. J Exp Med 207(13):2843–2854
Garrido D, Dallas DC, Mills DA (2013) Consumption of human milk glycoconjugates by infant-associated bifidobacteria: mechanisms and implications. Microbiology 159(Pt 4):649–664
Garrido D, Ruiz-Moyano S, Kirmiz N, Davis JC, Totten SM, Lemay DG, Ugalde JA, German JB, Lebrilla CB, Mills DA (2016) A novel gene cluster allows preferential utilization of fucosylated milk oligosaccharides in Bifidobacterium longum subsp. longum SC596. Sci Rep 6:35045
Goulas TK, Goulas AK, Tzortzis G, Gibson GR (2007) Molecular cloning and comparative analysis of four beta-galactosidase genes from Bifidobacterium bifidum NCIMB41171. Appl Microbiol Biotechnol 76(6):1365–1372
James K, Motherway MO, Bottacini F, van Sinderen D (2016) Bifidobacterium breve UCC2003 metabolises the human milk oligosaccharides lacto-N-tetraose and lacto-N-neo-tetraose through overlapping, yet distinct pathways. Sci Rep 6:38560
Koropatkin NM, Cameron EA, Martens EC (2012) How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol 10(5):323–335
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259):680–685
Lewis ZT, Mills DA (2017) Differential Establishment of bifidobacteria in the breastfed infant gut. Nestle Nutr Inst Workshop Ser 88:149–159
LoCascio RG, Ninonuevo MR, Freeman SL, Sela DA, Grimm R, Lebrilla CB, Mills DA, German JB (2007) Glycoprofiling of bifidobacterial consumption of human milk oligosaccharides demonstrates strain specific, preferential consumption of small chain glycans secreted in early human lactation. J Agric Food Chem 55(22):8914–8919
Macfarlane GT, Steed H, Macfarlane S (2008) Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. J Appl Microbiol 104(2):305–344
Maldonado-Gomez MX, Martinez I, Bottacini F, O’Callaghan A, Ventura M, van Sinderen D, Hillmann B, Vangay P, Knights D, Hutkins RW, Walter J (2016) Stable engraftment of Bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe 20(4):515–526
Milani C, Lugli GA, Duranti S, Turroni F, Mancabelli L, Ferrario C, Mangifesta M, Hevia A, Viappiani A, Scholz M, Arioli S, Sanchez B, Lane J, Ward DV, Hickey R, Mora D, Segata N, Margolles A, van Sinderen D, Ventura M (2015) Bifidobacteria exhibit social behavior through carbohydrate resource sharing in the gut. Sci Rep 5:15782
Milani C, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, Belzer C, Delgado Palacio S, Arboleya Montes S, Mancabelli L, Lugli GA, Rodriguez JM, Bode L, de Vos W, Gueimonde M, Margolles A, van Sinderen D, Ventura M (2017) The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev. https://doi.org/10.1128/MMBR.00036-17
Miwa M, Horimoto T, Kiyohara M, Katayama T, Kitaoka M, Ashida H, Yamamoto K (2010) Cooperation of beta-galactosidase and beta-N-acetylhexosaminidase from bifidobacteria in assimilation of human milk oligosaccharides with type 2 structure. Glycobiology 20(11):1402–1409
Moller PL, Jorgensen F, Hansen OC, Madsen SM, Stougaard P (2001) Intra- and extracellular beta-galactosidases from Bifidobacterium bifidum and B. infantis: molecular cloning, heterologous expression, and comparative characterization. Appl Environ Microbiol 67(5):2276–2283
O’Connell KJ, O’Connell Motherway M, O’Callaghan J, Fitzgerald GF, Ross RP, Ventura M, Stanton C, van Sinderen D (2013) Metabolism of four alpha-glycosidic linkage-containing oligosaccharides by Bifidobacterium breve UCC2003. Appl Environ Microbiol 79(20):6280–6292
O’Connell Motherway M, Fitzgerald GF, van Sinderen D (2011) Metabolism of a plant derived galactose-containing polysaccharide by Bifidobacterium breve UCC2003. Microb Biotechnol 4(3):403–416
O’Connell Motherway M, Kinsella M, Fitzgerald GF, van Sinderen D (2013) Transcriptional and functional characterization of genetic elements involved in galacto-oligosaccharide utilization by Bifidobacterium breve UCC2003. Microb Biotechnol 6(1):67–79
O’Riordan K, Fitzgerald GF (1998) Evaluation of bifidobacteria for the production of antimicrobial compounds and assessment of performance in cottage cheese at refrigeration temperature. J Appl Microbiol 85(1):103–114
Riviere A, Selak M, Lantin D, Leroy F, De Vuyst L (2016) Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol 7:979
Roger LC, Costabile A, Holland DT, Hoyles L, McCartney AL (2010) Examination of faecal Bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life. Microbiology 156(Pt 11):3329–3341
Ruiz L, Motherway MO, Lanigan N, van Sinderen D (2013) Transposon mutagenesis in Bifidobacterium breve: construction and characterization of a Tn5 transposon mutant library for Bifidobacterium breve UCC2003. PLoS ONE 8(5):e64699
Sela DA (2011) Bifidobacterial utilization of human milk oligosaccharides. Int J Food Microbiol 149(1):58–64
Smilowitz JT, Lebrilla CB, Mills DA, German JB, Freeman SL (2014) Breast milk oligosaccharides: structure-function relationships in the neonate. Annu Rev Nutr 34:143–169
Tailford LE, Crost EH, Kavanaugh D, Juge N (2015) Mucin glycan foraging in the human gut microbiome. Front Genet 6:81
Terzaghi BE, Sandine WE (1975) Improved medium for lactic streptococci and their bacteriophages. Appl Microbiol 29(6):807–813
Turroni F, Bottacini F, Foroni E, Mulder I, Kim JH, Zomer A, Sanchez B, Bidossi A, Ferrarini A, Giubellini V, Delledonne M, Henrissat B, Coutinho P, Oggioni M, Fitzgerald GF, Mills D, Margolles A, Kelly D, van Sinderen D, Ventura M (2010) Genome analysis of Bifidobacterium bifidum PRL2010 reveals metabolic pathways for host-derived glycan foraging. Proc Natl Acad Sci USA 107(45):19514–19519
Turroni F, Peano C, Pass DA, Foroni E, Severgnini M, Claesson MJ, Kerr C, Hourihane J, Murray D, Fuligni F, Gueimonde M, Margolles A, De Bellis G, O’Toole PW, van Sinderen D, Marchesi JR, Ventura M (2012) Diversity of bifidobacteria within the infant gut microbiota. PLoS ONE 7(5):e36957
Turroni F, Milani C, Duranti S, Ferrario C, Lugli GA, Mancabelli L, van Sinderen D, Ventura M (2018a) Bifidobacteria and the infant gut: an example of co-evolution and natural selection. Cell Mol Life Sci 75(1):103–118
Turroni F, Milani C, Duranti S, Mahony J, van Sinderen D, Ventura M (2018b) Glycan utilization and cross-feeding activities by bifidobacteria. Trends Microbiol 26(4):339–350
Urashima T, Asakuma S, Leo F, Fukuda K, Messer M, Oftedal OT (2012) The predominance of type I oligosaccharides is a feature specific to human breast milk. Adv Nutr 3(3):473S–482S
van den Broek LA, Hinz SW, Beldman G, Vincken JP, Voragen AG (2008) Bifidobacterium carbohydrases-their role in breakdown and synthesis of (potential) prebiotics. Mol Nutr Food Res 52(1):146–163
Ward RE, Ninonuevo M, Mills DA, Lebrilla CB, German JB (2007) In vitro fermentability of human milk oligosaccharides by several strains of bifidobacteria. Mol Nutr Food Res 51(11):1398–1405
Wells JM, Wilson PW, Le Page RW (1993) Improved cloning vectors and transformation procedure for Lactococcus lactis. J Appl Bacteriol 74(6):629–636
Yoshida E, Sakurama H, Kiyohara M, Nakajima M, Kitaoka M, Ashida H, Hirose J, Katayama T, Yamamoto K, Kumagai H (2012) Bifidobacterium longum subsp. infantis uses two different beta-galactosidases for selectively degrading type-1 and type-2 human milk oligosaccharides. Glycobiology 22(3):361–368
DvS, MS and MOM conceived the study. VA, JOS and MOM performed the experiments with the help of BS and CL. FB performed the bioinformatics analyses. DvS, FB and VA wrote the manuscript. All authors read and approved the final manuscript.
We thank Dr. Bas Kuiper and Dr. Eric Benjamins for their support in performing this study.
AV, FB, JOS, MOM and DvS have no competing interests. MS, BS, and CL are employees of Friesland Campina.
Availability of data and materials
The data supporting the conclusions of this article are available and included within the article.
Consent for publication
Ethics approval and consent to participate
This work was financially supported by FrieslandCampina. DvS, VA, FB and MOM are members of APC Microbiome Ireland, which is a research centre funded by Science Foundation Ireland (SFI), through the Irish Government’s National Development Plan. The authors and their work were supported by SFI (Grant SFI/12/RC/2273), FEMS Research Grant FEMS-RG-2016-0103 and HRB (Grant No. 513 PDTM/20011/9).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
List of bifidobacterial genes used for comparative purposes. Figure S1. In silico analysis and functional characterization of β-galactosidases. Figure S2. SDS-PAGE of purified proteins.
About this article
Cite this article
Ambrogi, V., Bottacini, F., O’Sullivan, J. et al. Characterization of GH2 and GH42 β-galactosidases derived from bifidobacterial infant isolates. AMB Expr 9, 9 (2019). https://doi.org/10.1186/s13568-019-0735-3
- Infant gut microbiota